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CE4
COST-EFFECTIVENESS OF CAPECITABINE IN
COMBINATION WITH DOCETAXEL VERSUS
DOCETAXEL MONOTHERAPY IN PATIENTS
WITH ADVANCED AND/OR METASTATIC
BREAST CANCER IN FRANCE
Lilliu H1, Le Pen C1, Priol G1, Perez-Niddam K2,Aultman R2,
Garrison L3
1Clp-santé, Paris, France; 2Roche, Neuilly sur Seine, France;
3Roche Pharmaceuticals, Palo Alto, CA, USA
OBJECTIVES: To evaluate the cost effectiveness of
capecitabine + docetaxel combination versus docetaxel
alone in the treatment of advanced and/or metastatic
breast cancer in France. METHODS: This analysis was
based on primary data from an open-label, randomized,
multi-centre phase III clinical trial (SO14999). Unit costs
reﬂecting the French economic context was attached to
patients’ use of resource, i.e. reference tariffs for consul-
tations, daily treatment costs for drugs and mean cost per
DRG for hospitalizations. Direct medical costs were ana-
lyzed from a “payer” perspective, including payments
from the public health insurance, private supplementary
health insurers, and patients’ co-payment. Signiﬁcant dif-
ferences in costs were identiﬁed with a Student’s t-test for
the means. To calculate incremental cost-effectiveness, the
additional cost in the capecitabine arm was divided by
the additional years of life saved. The time horizon of the
clinical trial was 15 months and cost and health effects
were not discounted. RESULTS: Survival was longer in
the combination arm (mean 442 days versus 352 days).
The cost of capecitabine amounted to €1786, while the
cost of docetaxel was signiﬁcantly reduced in the combi-
nation group (€6089 versus €7856; p < 0.0001). None of
the other cost components differed between treatment
groups, and the overall direct medical cost was compa-
rable in the combination group (€9888 ± 343) and in the
monotherapy group (€9852 ± 378; p = 0.9436). The addi-
tional cost in the combination arm was €36 and the clin-
ical beneﬁt was 0.23 life-year saved. Thus, the cost per
life-year saved ratio was estimated to €157. CONCLU-
SIONS: Capecitabine/docetaxel combination appears as a
highly cost-effective strategy in comparison to docetaxel
monotherapy in the treatment of advanced or metastatic
breast cancer in France, while these results derived from
a randomized clinical trial need to be conﬁrmed in current
practice.
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RESPONSIVENESS TO CHANGE OF THE SHORT
FORM (SF)-12 HEALTH STATUS INSTRUMENT IN
PATIENTS WITH CEREBROVASCULAR DISEASE
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OBJECTIVES: The generic Short Form (SF)-36 is one of
the most commonly used health status instruments in
patients with cerebrovascular disease. However, a respon-
siveness to change—a pre-requisite for evaluative pur-
poses—has not yet been assessed for neither the SF-36 
nor its shortened version, the SF-12. Responsiveness to
change describes the ability of health status instruments
to detect clinically meaningful changes in HRQoL
(health-related quality of life) over time. The main objec-
tive of the present study was, therefore, to determine
responsiveness to change of the SF-12 questionnaire in
patients with stroke and TIA. METHODS: Patients with
stroke/TIA were included at admission to one of the four
participating hospitals. HRQoL was assessed with the
Physical (PCS-12) and Mental (MCS-12) Component
Summary scales at baseline and after 12 months. Respon-
siveness to change was determined with the standardized
response mean (SRM) and classiﬁed as small (SRM
0.20–0.49), moderate (0.50–0.79) or large (≥0.80). SRMs
were calculated separately for patients after stroke and
TIA, and according to stroke severity as measured with
the NIH (National Institutes of Health) stroke scale.
RESULTS: A total of 558 patients was included (55%
men, mean (standard deviation) age 65 (13) years; 45%
women, 69 (14) years). Indications for admission were
stroke (74%) and TIA (26%). In patients with stroke,
SRMs were moderate for both the PCS-12 (SRM 0.5;
absolute change -5.9 (12)) and the MCS-12 (SRM 0.5; 
-6.6 (13)). In patients with TIA, SRMs were below 0.2
for the PCS-12 (absolute change -0.7 (11)) and 0.3 for
the MCS-12 (-3.7 (11)). SRMs increased with stroke
severity as indicated by the NIH stroke scale score. CON-
CLUSIONS: The SF-12 summary scales show a moder-
ate responsiveness to change in patients after stroke.
Responsiveness to change was higher in patients with
increased stroke severity.
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PERFORMANCE OF THE EQ-5D IN PATIENTS
WITH IRRITABLE BOWEL SYNDROME
Bushnell DM1, Martin ML1, Ricci JF2
1Health Research Associates, Inc, Mountlake Terrace, WA,
USA; 2Novartis Pharma AG, Basel, Switzerland
OBJECTIVE: The EQ-5D is a standardized, non-
disease-speciﬁc instrument for describing and valuing
patients’ health-related quality of life. The purpose of this
study is to evaluate psychometric properties of the EQ-
5D in patients with irritable bowel syndrome (IBS).
METHODS: Data from 4 European studies was assessed:
2 studies from the UK (n = 161 and 305 IBS patients), 
1 from Spain (n = 517), and 1 from Germany (n = 100).
Measures used to examine the EQ-5D included the SF-
36, the Irritable Bowel Syndrome—Quality of Life (IBS-
QOL) scale, and both subjective and clinical global
assessments of IBS. Convergent validity was assessed
using SF-36 and IBS-QOL data, discriminate validity
using global ratings of severity, and responsiveness by
subjective and physician assessment of condition. All sub-
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jects were clinically typed into IBS category: constipation,
diarrhea or alternating. RESULTS: Correlations between
the EQ-5D visual analogue scale (EQ VAS) score and the
SF-36 subscales (available in the UK studies) were mod-
erate to high (r = 0.33 to 0.71, p < 0.01) with lower asso-
ciations seen with the mental health scores. Correlations
with the IBS-QOL (available in all studies) ranged from
0.33 to 0.54 (p < 0.01). Levels of responses to EQ-5D
items and the EQ VAS score were signiﬁcantly better for
control patients than for patients with IBS (all p < 0.01).
The EQ VAS was able to discriminate between levels of
pain severity (quartiles, p < 0.001; mild/moderate/severe,
p < 0.05) and general health severity (mild/moderate/
severe, p < 0.001). The EQ VAS was responsive in patients
with both a self-perceived and physician-rated improve-
ment in condition at 1 year (10.7-pt improvement, effect
and 8.7-pt improvement, ES = 0.47, respectively). CON-
CLUSIONS: The EQ-5D performs quite well in compar-
ison to the SF-36 (general) and IBS-QOL (disease-speciﬁc)
patient reported outcomes. It is a brief, valid and respon-
sive measure that can used to generate preference-based
valuations of health-related quality of life in patients with
IBS.
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PREVALENCE AND QUALITY OF LIFE OF
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OBJECTIVES: Estimate the prevalence and the quality 
of life of restless legs syndrome (RLS) in the French 
population 18 years of age or older. METHODS: A 
population-based survey was conducted among 10,000
adults through face to face interviews by using the quota
sampling method (on age, sex, geographical living 
area, economic working class and woman working
status). The screening was made with the 4 International
RLS Study Group (IRLSSG) criteria. Quality of life was
assessed with the SF-36 questionnaire among subjects 
suffering from RLS and a control group of 540 subjects
randomly selected among the global sample. RESULTS:
The population surveyed was representative of the 
French population. The lifetime prevalence of RLS (at
least one symptom episode in past life) was estimated:
9.2%, IC 95% = [8.3%; 10.2%]. The annual prevalence
of RLS (at least one symptom episode in the past year)
was estimated: 8.7%, IC 95% = [7.7%; 9.6%]. Among
RLS population, the sex ratio women to men was 2 to 
1 and the mean age at the time of the study was 48.5
years versus 46.5 years in the control group. After adjust-
ment on age and sex, all quality of life dimensions 
were worse in the RLS population than in the control
group: Physical Functioning: 82.7 vs. 87.2 (p < 0.001);
Role Functioning: 74.4 vs. 84.6 (p < 0.001); Bodily 
Pain: 63.7 vs. 75.1 (p < 0.001); General Health: 62.7 vs.
69.6 (p < 0.001); Vitality: 53.4 vs. 59.6 (p < 0.001); 
Social Functioning: 77.9 vs. 85.2 (p < 0.001); Reported
Health Transition: 75.0 vs. 84.0 (p < 0.001); Mental
Health: 62.3 vs. 68.3 (p < 0.001). CONCLUSIONS: RLS
is a frequent disease, it affects 9% of the French adult
population. This prevalence is consistent with the ﬁnd-
ings of studies from other countries. RLS has a signiﬁcant
impact on quality of life, as measured by the SF-36 
questionnaire.
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